Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,951 total articles
Nvidia just extended its hyperscaler dominance: a multiyear deal with Meta to supply Blackwell/Rubin GPUs and Grace/Vera CPUs meaningfully increases revenue visibility for 2026. The trade is to buy NVDA on a confirmed breakout with a stop below recent support and a target near the 52-week high — a mid-term swing that balances momentum and valuation…
I upgraded Celestica (CLS) to a tactical long after the stock found consistent support near $286. The balance sheet, free cash flow generation and an accepted normal course issuer bid give the company optionality even if near-term customer mix is noisy. This trade idea lays out a mid-term (45 trading days) plan with entry, stop and target and the k…
BitMine Immersion Technologies is effectively an ETH treasury with a public equity wrapper. The stock is trading on depressed technicals near $20 while the company controls meaningful Ethereum reserves. This trade idea targets a mid-term re-rating as crypto sentiment stabilizes and ETH price recovers.
Itron's recent operational momentum, strategic tuck-ins (Urbint and Locusview) and exposure to a growing smart-utilities market give the stock a favorable risk/reward. Valuation metrics (P/E ~15, EV/EBITDA ~12) and robust free cash flow underpin a swing trade setup with defined entry, stop and target levels.
Tesla looks past the carnage of 2025 and is showing signs of a sustained comeback: positive free cash flow of $6.22B, a market cap near $1.56T and technical momentum combine with a large battery storage TAM to justify a tactical upgrade. This trade plan targets $480 with a $375 stop for a mid-term push tied to improving fundamentals and several nea…
Tourmaline Oil offers amplified exposure to North American natural gas demand while trading at a valuation that, in my view, understates the company’s free-cash-flow potential and capital returns optionality. With management putting their own capital to work, I’m initiating a risk-sized long with a defined stop and target over a 180 trading day hor…
Uber is no longer just a ride-hailing company. With nascent robotaxi deployments, expanded delivery markets in Europe, and ongoing AI partnerships, the company pairs a platform-level moat with profitable unit economics. At ~$72.60 today, Uber looks like a reasonable long for investors willing to hold for operational progress in autonomy and margin …
Snap reported 946 million monthly active users and beat Q4 estimates with $1.72B revenue. The shares are trading near a 52-week low while free cash flow and revenue growth provide a tangible path to multiple expansion. We lay out a long trade with entry, stop and target and the catalysts and risks that matter.
Amazon's ~20% drawdown from last year's highs has traders second-guessing exposure, but underlying valuations and early enterprise AI wins suggest AWS is set to convert accelerated AI demand into outsized cash flow. This trade idea outlines a long entry, clear stop, price target, and the drivers that could flip negative investor sentiment.
Global Payments (GPN) is trading at bargain multiples after a long correction. Management’s 2026 EPS guide and a $2.5B buyback create a path for a dramatic re-rating. This trade idea lays out an entry at current levels, a tight stop below the recent range, and an ambitious target that assumes multiple expansion as investors re-price the company tow…
Pfizer is offering a beaten-down valuation, a 6%+ yield, and improving clinical momentum. The stock looks attractive for a mid-term swing trade: entry near current levels, stop below the support band, target at a multiple re-rating if product wins and pipeline readouts continue to surprise. This is a trade, not a deep-value buy-and-hold call; risk …
Hinge Health combines fast top-line growth with improving margins and substantial free cash flow. Recent Q4 results beat expectations, and management's 2026 guide points to continued revenue growth and non-GAAP earnings expansion. The trade idea outlines a long trade with precise entry, stop and target, a rationale grounded in numbers, and a balanc…
Seaboard (SEB) combines a cash-generative pork business with a growing Marine fleet and attractive valuation. Fundamentals and recent policy tailwinds for shipping make a mid-term long trade compelling from the current ~$4,955 level. Entry at $4,955, target $5,400, stop $4,680; horizon mid term (45 trading days).
Heron Therapeutics is trading near the bottom of its recent range despite product revenue upside and board additions. Valuation is modest by biotech standards (market cap ~$232M, EV ~$315M) but cash flow is negative and shorts are crowded. This is a tactical, mid-term swing trade: enter at $1.23, stop $0.95, target $1.85 over ~45 trading days with …
Cloudflare reported accelerating revenue and deal activity driven by agentic AI workloads. The balance of robust cash generation and an expensive valuation creates a tactical long opportunity: enter around $190.47, target $300, stop $170, horizon 180 trading days. Key risks include stretched multiples, competition, and execution on margin expansion…
IREN is sitting at a crossroads: the stock is volatile after a weak quarter, but the company has secured financing, a confirmed large hyperscaler contract, and accelerating GPU capacity that should transform revenue mix from crypto to recurring AI cloud sales. This trade targets a re-rate as ARR ramps and institutional demand increases around index…
Leadership clarity at Disney is a meaningful positive, but the company’s turnaround — streaming profitability, park strength, potential asset moves — takes time. This trade idea sets a clear entry at $107.59 with a $130 target and a $95 stop, framed as a position trade that expects catalysts and execution to unfold over several months.
Smith & Wesson (SWBI) has finished its relocation and is generating positive free cash flow again. At a market cap near $527M and free cash flow of $21.3M, the stock looks reasonably supported despite a high P/E. This trade idea targets $15.50 over a 180-trading-day horizon with a tight structural stop at $10.80 to limit downside if margins deterio…
IREN has swung from crypto-dependent volatility toward an AI infrastructure identity. Recent financing, a large Microsoft contract and a 1.4 GW facility coming online give the stock a tangible re-rating path. The trade: a long entry at current levels with a defined stop and target to ride a mid-to-long-term re-rating while respecting execution risk…
Micron's latest SSD lineup — purpose-built for generative AI workloads — is creating durable demand from hyperscalers. Backed by robust fundamentals (market cap ~$462B, EPS $10.58, FCF $4.65B) and tightening memory supply, this is a tactical long for investors willing to accept cyclicality in exchange for asymmetric upside.
Upstart’s underlying AI platform is moving from proof-of-concept to clear commercial scale. Q4 showed big originations growth and profitable inflection points; the market has punished the stock into an attractive risk/reward window. We upgrade to Buy and lay out a mid-term (45 trading days) swing trade with entry, stop, and target.
ATI Inc. sits squarely in the path of a potential jet-engine-driven cycle. The company’s high-performance materials and superalloys are critical to OEM ramps and aftermarket repairs. Fundamentals (strong free cash flow, high ROE) support a tactical long, but valuation and stretched technicals demand disciplined sizing and a clear stop. Trade plan: …
Freshworks (FRSH) sold off sharply after conservative guidance, but the company still generates meaningful free cash flow, has double-digit revenue growth, and trades at a reasonable multiple to FCF and sales. With RSI in deeply oversold territory and short interest elevated, this is a tactical long for traders who want a defined-risk exposure to a…
PayPal is trading at bargain multiple levels after a bruising earnings cycle and management turnover. With market cap near $37.6B, EV/EBITDA around 5.4x, free cash flow of $5.56B and a P/E near 7x, the risk/reward favors a long position over a 180-trading-day horizon. Technicals show an oversold RSI and compressed multiple; catalysts include a new …
Nektar Therapeutics just cleared a major perception hurdle: clinical maintenance data in atopic dermatitis (AD) tied to rezpegaldesleukin (rezpeg) have driven investor enthusiasm and put the shares into a breakout. Fundamentals remain early-stage — revenues are modest, EPS negative and free cash flow is negative — but the clinical differentiation, …
